Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service DBS & VNS cases in Oklahoma: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (103 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 124 | 24% |
| 2020 | 3 | 171 | 28% |
| 2021 | 4 | 189 | 34% |
| 2022 | 2 | 128 | 38% |
| 2023 | 1 | 128 | 42% |
| 2024 | 3 | 152 | 44% |
| 2025 from claims | – | 135 109–158 | 46% |
| 2026 forecast | – | 138 108–173 | 46% |
| 2027 forecast | – | 141 104–186 | 47% |
| 2028 forecast | – | 144 102–199 | 48% |
| 2029 forecast | – | 147 100–211 | 49% |
| 2030 forecast | – | 151 99–224 | 49% |
Deep brain and vagus nerve stimulator implants. Professional codes (what the surgeon bills): CPT 61863, 61867, 61885, 61886, 64568; the hospital bills MS-DRG 040, 041, 042.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Oklahoma; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 24% inpatient hospital, 76% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 18 | 941−0.6%/yr | −0.6%/yr | 0.4 | 2% | 1,460 in 2030+7.6%/yr |
| Florida | 13 | 844+0.5%/yr | +0.5%/yr | 0.4 | 2% | 1,550 in 2030+11%/yr |
| North Carolina | 8 | 293−8.9%/yr | −8.9%/yr | 0.3 | 0% | 440 in 2030+7.1%/yr |
| Virginia | 5 | 275−0.4%/yr | −0.4%/yr | 0.3 | 0% | 420 in 2030+7.4%/yr |
| Tennessee | 4 | 252+1%/yr | +1%/yr | 0.3 | 0% | 270 in 2030+1.2%/yr |
| Georgia | 3 | 211+0.2%/yr | +0.2%/yr | 0.2 | 0% | 230 in 2030+1.1%/yr |
| Kentucky | 5 | 203−3.5%/yr | −3.5%/yr | 0.4 | 0% | 330 in 2030+8.4%/yr |
| Alabama | 4 | 187−6.5%/yr | −6.5%/yr | 0.4 | 0% | 190 in 2030+0.5%/yr |
| South Carolina | 2 | 151−3.2%/yr | −3.2%/yr | 0.2 | 0% | 260 in 2030+9.8%/yr |
| Louisiana | 2 | 151−6.2%/yr | −6.2%/yr | 0.4 | 0% | 1,100 in 2030+39%/yr |
| Maryland | 1 | 111−4.1%/yr | −4.1%/yr | 0.1 | 0% | 120 in 2030+1.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 4 | 180+1.4%/yr | +1.4%/yr | 0.40.9× | 0% | 140 in 2030−3.7%/yr |
| Aneurysm & intracranial embolization | 2 | 164+3.5%/yr | +3.5%/yr | 0.30.8× | 0% | 450 in 2030+18%/yr |
DBS & VNS in every state, and its device makers · Every procedure market in Oklahoma · Every state · Compare with Texas
Medtronic leads with 54% of company spending on these surgeons in 2025, +3 pts on 2024.
In 2025, 6 companies reported engagement with Oklahoma’s surgeons worth $35K in consulting, speaking, meals and travel tied to these products, about $12K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 56 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.